Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Of the three Dow Jones companies reporting, only Amgen is in a buy zone.

Amgen, Other Dow Jones Companies Highlight Earnings Calendar

THOUSAND OAKS, Calif. , Aug. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of the U.S. financial markets.

AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Exploring Analyst Estimates for Amgen (AMGN) Q2 Earnings, Beyond Revenue and EPS

Gilead Sciences

Vertex Pharmaceuticals

In the bustling world of biotechnology, innovation remains the cornerstone of growth. Some biotech stocks, known for their groundbreaking research and rapid adaptation to health challenges, are particularly well-positioned to do well in the future.

The Top 3 Biotech Stocks to Buy Now Summer 2024

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?

AbbVie

AstraZeneca

Bristol-Myers

Johnson & Johnson

Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.

Pharma companies less concerned after hearing from US on negotiated prices for Medicare

In the closing of the recent trading day, Amgen (AMGN) stood at $334.85, denoting a +0.16% change from the preceding trading day.

Amgen (AMGN) Advances But Underperforms Market: Key Facts

Amgen stock is up 45% over the past year, driven by the excitement around the trials of its obesity drug.

Amgen Surges As Weight-Loss Trials Drive Excitement

e.l.f. Beauty

Netflix

Investors have been on a roller coaster ride for the past four years. One of the longest bull markets in history was brought to a screeching halt by the global pandemic.

3 Fabulous Growth Stocks to Buy and Hold Forever

International Paper

Iron Mountain

Labcorp Holdings Inc

Merck

Super Micro Computer

No one knows when the next S&P 500 crash will hit. But everyone should know which stocks to watch out for.

Look Out Below If You Still Own 7 Stocks When The Crash Comes

Arcutis Biotherapeutics

Axsome Therapeutics

ImmunityBio

Madrigal Pharmaceuticals

Intellia Therapeutics

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.

7 Biotech Stocks to Keep on Your Clinical Radar

Apple

Costco

Occasionally, hot stocks can get that much hotter in a move that can only be described as a “melt-up.” Such extreme share price action can be like the reverse of a stock meltdown, whereby a stock crashes rapidly, like in late February 2020.

3 Stocks That Are Melting Up. Is There Room to Run?

Dow Jones biotech giant Amgen, along with Nvidia stock and Coinbase Global, are in or near buy zones on the stock market today.

Dow Jones Leader Amgen, Nvidia Stock, Coinbase In Or Near Buy Zones

Abbott Labs

Lowe's

Nordson

NIKE

Parker-Hannifin

S&P Global

Target

Visa

These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare, technology, and finance, offering potential for portfolio diversification.

10 Best Dividend Growth Stocks to Buy and Hold Forever

NVIDIA

NVIDIA, Meta and Amgen Galaxy Gaming are included in this Analyst Blog.

The Zacks Analyst Blog NVIDIA, Meta and Amgen Galaxy Gaming

Halozyme Therapeutics

United Therapeutics

Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals.

3 Biotech Stocks to Buy Now: Q3 Edition

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

Amgen currently continues its pattern of quarterly dividend increases. Furthermore, Amgen demonstrated product-sales growth in the first quarter.

What Is the Dividend Payout for Amgen Stock?

Cisco Systems

Dow Inc

Home Depot

Coca-Cola

24/7 Insights While trailing the other indices this year, many of the 30 Dow stocks offer tremendous value.

6 Dow Jones Dividend Stocks to Buy Hand Over Fist

AbbVie is poised to keep a 52-year streak of dividend hikes going. Amgen offers more than a dividend with its promising pipeline.

3 Dividend Growth Stocks to Buy and Hold

Accenture Plc

Automatic Data Processing

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

American Water Works

Booz Allen Hamilton Hld

SPDR Bloomberg 1-3 Month T-Bill ETF

Booking Hlds

Blackrock Inc

Broadridge Financial

CME Group

Canadian National Railway Company

Canadian Pacific Kansas City Limited

Camden Property

Retirement strategies are not one-size-fits-all due to individual variables like nest egg size, lifestyle costs, and goals. Conventional retirement plans like real estate investing and the 4% rule have pros and cons, influencing personal retirement strategies. My retirement plan prioritizes passive income generation, dividend growth, and active portfolio management to avoid forced asset sales and ensure financial freedom.

If I Had To Retire Today, Here's How I'd Do It

News for Amgen Stock (AMGN)